上市捷报丨沙利文助力江苏荃信生物医药股份有限公司成功赴港上市(2509.HK)

Jiangsu Quanxin Biomedical Co., Ltd. (Stock Code:2509.HK) on2024year03month20Successfully logged into the Hong Kong capital market main board on2015Since its establishment, the company has been focusing on autoimmune and allergic diseases, establishing a broad pipeline of drugs covering skin, rheumatism, respiratory, and digestive tract diseases. As of2024year3month2Today, the company is among the Chinese enterprises that have gained the most in the field of autoimmune and allergic diseasesINDOne of the companies that has approved the candidate drug. In addition, the company is one of the few biotechnology companies in China that focuses on autoimmune and allergic diseases and has mature commercial-scale in-house production capabilities. Frost & SullivanFrost & Sullivan,Frost & Sullivan, referred to below as the 'Frost & Sullivan team', provides exclusive industry advisory services for the listing of Jiangsu Quanxin Biomedical Co., Ltd. We hereby extend our warmest congratulations on its successful listing.

Jiangsu Quanxin Biomedical Co., Ltd. (hereinafter referred to as 'Quanxin Biology') was established on2024year03month20The company plans to go public on the 1st of July12,046,400shareHShares, including Hong Kong shares issued1,204,800Shares, International Offering10,841,600Shares. The offer price is per share19.80HK$, with the net amount of raised funds being approximately1.63HK$10 billion.

During the process of listing in Hong Kong this time, Frost & Sullivan mainly undertook the following tasks: helping the issuer accurately and objectively understand its positioning in the target market, using objective market data to discover, support and highlight the issuer's competitive advantages, assisting the issuer, investment banks and other intermediaries in completing the writing of relevant parts of the prospectus (such as overview, competitive advantages and strategy, industry overview, business and other important chapters), helping the issuer complete communication with the Hong Kong Stock Exchange and investors, assisting investors in quickly understanding the market ecosystem and competitive landscape, and assisting the issuer in completing feedback on various industry-related issues from the Hong Kong Stock Exchange, etc.

Investment highlights

The company is a leading national enterprise in innovative drugs for autoimmune system diseases and allergic diseases;

The company is a biotechnology company with mature commercial-scale internal production capabilities;

The company's production facilities comply with those of China, the United States, and the European Union.cGMPStandard, with an annual production capacity of about300 kgTherapeutic antibody;

The company has strong R&D and innovation capabilities, and its extensive pipeline layout has achieved multi-level synergies from early R&D to clinical resource sharing, patient education, and commercialization;

The company's management team has rich industry experience, with expertise in R&D, clinical operations,CMCAnd has rich and complementary experience in business development.

According to a report by Frost & Sullivan:

As of2024year3month2Today, the company is among the Chinese enterprises that have gained the most in the field of autoimmune and allergic diseasesINDOne of the companies that approved the candidate drug;

As of2024year3month2day, according toINDThe company ranks first in China in terms of the number of approved dermatological candidate biologics and indications;

As of2024year3month2Today, the company is one of the few biotechnology companies in China that focuses on autoimmune and allergic diseases and has mature commercial-scale in-house production capabilities;

projected2030The Chinese market for drugs for autoimmune and allergic diseases will grow to415billion US dollars, since2022The compound growth rate starting from the year21.1%The market prospects are broad.

Autoimmune and allergic diseases in China

Overview of the Biopharmaceutical Market

Autoimmune diseases are related to immune system disorders, which lead to an abnormal activation of the immune system and cause the body to attack and damage its own tissues incorrectly. Autoimmune diseases include100There are various types of diseases that can affect almost any part of the body, such as the skin, joints, muscles, bones, and digestive system.

Allergic diseases are hypersensitivity conditions of the immune system caused by contact with allergens in the external environment (such as pollen, food, drugs, insect bites, etc.), and can also affect multiple organs. Autoimmune and allergic diseases can trigger severe symptoms such as acute pain, persistent itching, and physical damage. In some cases, they may even lead to life-threatening complications or be fatal.

Source: Frost & Sullivan report

Autoimmune and allergic diseases are the second largest therapeutic area globally.2022In [year], the market scale of autoimmune and allergic drugs in China was90billions, of which biopharmaceuticals account for20.4%estimate2030In 2023, China's market for drugs for autoimmune and allergic diseases will grow to415billion US dollars, since2022The compound annual growth rate starting from next year can reach21.1%The proportion of biologics increased to about60%Given favorable government policies and the increased R&D investment in biopharmaceuticals by domestic pharmaceutical developers in China to seize market opportunities, it is expected that the Chinese market for autoimmune and allergic diseases will see more innovative biopharmaceuticals suitable for a wider range of indications in the future.

Source: Frost & Sullivan report

Autoimmune and allergic diseases in China

Market competition pattern of biopharmaceuticals

The competition in the biopharmaceutical market for autoimmune and allergic diseases in China is fierce, as of2024year3month2On the same day, the following figure lists the main domestic companies in this market. Among them, Quanjin Biology has received the mostINDOne of the companies that has approved the candidate drug.

In the field of innovative drugs for autoimmune and allergic diseases in China, Frost & Sullivan has served companies such as Hengrui Medicine, Sanyo HealthCare, Fosun Pharma, Rongchang Biotech, China National Biotec Group Co., Ltd., Kangfang Biotech, CanSino Biologics, BeiGene Biotech, Innovent Biologics, Xinda Biotech, ZaiDi Biologics, Everest Biologics, Yunding New Hope, Mabtech Biologics, Lingke Pharmaceutical, Bao'an Biologics, Novogene, Hengyi Biotech, Tian Guangshi, and Mabtech Pharmaceuticals.

View the full prospectus of Tsuen Shin Biology

Frost & Sullivan integrates the globe.63years of consulting experience,26Frost & Sullivan provides dedicated services to the booming Chinese market, with a global perspective, helping clients accelerate their business growth and achieve benchmark positions in industry growth, innovation, and leadership. The large health industry is one of the core areas of focus for Frost & Sullivan. Recently20For many years, the Frost & Sullivan team has provided financing and financial advisory services to hundreds of outstanding domestic and international biopharmaceutical, medical device, healthcare services, and internet healthcare companies.IPO listingIndustry consulting, strategic consulting, management consulting, and other services. Successful listings include: Meizhongjiahe (2453.HK), WuXi AppTec (2268.HK), Anuo MedicineNASDAQ:ANL), Neusoft Xikang （9686.HK), Youzhiyou2496.HK), Yiming Angke 1541.HK ), Colombo Bay6 990.HK), LaiKai Medicine 2105.HK), Kedex Group2487.HK), Lvz Bio2480.HK), Meis Health 2415.HK), Yaohua MedicinePHECR), Zhongjin Medical （NASDAQ:ZJYL), Yisheng Biology NASDAQ:YS ), Beautiful Countryside 2373.HK), Kangfeng Biology6922.HK), Bao'an Biology6955.HK), Ideasight1244.HK), Meihao Medical1947.HK), Gaoshi Medical (2407.HK), Lepu Xintai2291.HK), Genstar Biotech9877.HK), HealthyuanJCARE.SW), Leopu MedicalLEPU.SW), DINGDANG HEALTH9886.HK), Baidu Map Suggest (2315.HK), Zhiyun Health9955.HK), MeinGene6667.HK),Prenetics（PRE.NASDAQ), Yunkang Group2325.HK), Ruike Biotechnology2179.HK), Leepu Biotech2157.HK), Clear Medical (1406.HK), Baisinkan2185.HK), Yonghe Medical (2279.HK), Kailaiying6821.HK), Beihai Kangcheng1228.HK), Gusheng Hall2273.HK), Eagle Eye Technology2251.HK), Clover Biotechnology2197.HK), minimally invasive robots2252.HK), and Yuhui Kaiman2256.HK), Kunbo Medical (2216.HK), Xianruida6669.HK), Kangsheng Global9960.HK), Medical Pulse Connect (2192.HK), Tengsheng Bo medicine2137.HK), Conoco (2162.HK), Chaogju Eye Hospital (2219.HK), Guichuangtong Bridge2190.HK), and Huang Medicine0013.HK), Keji Pharmaceutical2171.HK), Zhaoke Eye Hospital6622.HK), Nature MedicineUPC.NASDAQ), Sino Biologics (6600.HK), Zhaoyan New Drugs6127.HK), Novo Nordisk Health (6606.HK), Tianyan PharmaceuticalADAG.NASDAQ), Beikang Medical (2170.HK), Jianbimiao Miao Miao2161.HK), Minimally Invasive Cardiac Angioplasty (2160.HK), Ruili Medical Beauty2135.HK), Jiake Pharmaceutical1167.HK), and Bopan Medicine2142.HK), JD Health6618.HK), Deqi Medicine6996.HK), Rongchang Biology9995.HK), WuXi AppTec Genomics (2126.HK), Sinobiopharmaceuticals2096.HK), Yunding Xinyao1952.HK), Harvest Biotech6998.HK), ZaiDi Pharma9688.HK), Ocumivir1477.HK), Yongtai Biology6978.HK), Hype Pharma9989.HK), Kechuang Pharmaceutical9939.HK), Peijia Medical (9996.HK), Kangfang Biology9926.HK), Novartis HealthCare (9969.HK), Celestial BeingsIMAB.NASDAQ), Kanglonghua Cheng3759.HK), China Antibody3681.HK), Dongyao Pharmaceutical1875.HK), Yasheng Medicine6855.HK), Fosun Pharma (2696.HK), Hansoh Pharmaceutical3692.HK), Mabotech2181.HK), Founder Holdings1521.HK), Viva Biology1873.HK), CStone Pharmaceuticals2616.HK), Junshi Biology1877.HK), WuXi AppTec (2359.HK), Innovent Biologics1801.HK), Hualing Medicine2552.HK), BeiGene (6160.HK), Gelifarmaceuticals1672.HK), WuXi AppTec Biologics2269.HK), China Resources Medicine3320.HK), Yakult Scientific & Pharmaceutical2633.HK), and Huang China MedicineHCM.NASDAQ), Biotechnology1548.HK),BBILife Sciences1035.HK) and so on. According to the number of submission items, the Frost & Sullivan healthcare team is involved in medicalIPO listingMaintain an absolute leading position,2018till2023Year after year, it has always ranked first in market share.

since2019year7Since the listing of the first batch of companies on the Sci-tech Innovation Board, Frost & Sullivan reports have also been widely referenced in the prospectuses of leading Sci-tech Innovation Board-listed companies, including: Zhongyan Co., Ltd.688716.SH), Zhejiang Rongtai603119.SH), OptoGrid Technology 688450.SH ) , Hybrid Integration688249.SH), Wuxi Rilian688531.SH), Maolai Optics688502.SH), Kangwe Century688426.SH), coastal protein688137.SH), Novartis HealthCare (688428.SH), OPUMAI BIOLOGY688293.SH), minimally invasive electrophysiology688351.SH), Mengke Pharmaceutical688373.SH), Yifang Biology688382.SH), Jicui Pharmaceutical Health (688046.SH), Haiscot Biopharmaceuticals688302.SH), Rongchang Biology688331.SH), Rendu Biology688193.SH), Capital Pharmaceutical Holdings (688197.SH), and Yuanbiotech (688238.SH), YASIN Security688225.SH), Xidiwei688173.SH), MyWay Biotechnology688062.SH), Yarong Medicine688176.SH), BeiGene (688235.SH), Jiahemeikang688246.SH), DiZhe Medicine688192.SH), Novozymes688105.SH), Chengda Biology688739.SH), Gecko Micro688728.SH), Huaxi Biology688363.SH), Junshi Biology688180.SH), Zhejiang Genomics & Therapeutics Co., Ltd.688266.SH), Bai'ao Tai688177.SH), SinoCell (688520.SH) and others are considered one of the most powerful, professional, and influential industry research institutions in the industry. We hope to work with enterprises to understand industry trends, seize development opportunities, jointly promote innovation and upgrading of China's big health industry, and build a healthy future.